並列摘要
Antibody-drug conjugates (ADC) is one of the most important approach in recent cancer drug development. ADCs are composed of an antibody and biological active cytotoxic payloads through a specific linker and designed as a targeted therapy for the treatment of cancer patients. ADCs can target to the tumor cells through the antibody part by recognizing and binding to correspond tumor antigen. ADC drugs combine the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs.
延伸閱讀
- Pan, C. H. (2016). 開發以抗體作為載體搭載鉑類藥物並針對大腸直腸癌之標靶藥物 [master's thesis, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU201602119
- 黃日輝、闕文仁（1963）。新型抗生素之研究 第一報 Streptomyces sp. 680所生產抗生素之研究。化學，(52年4)，155-163。https://doi.org/10.6623/chem.1963023
- Hsieh, Y. Y. (2018). 整合生物資訊及實驗驗證應用於多靶藥理及老藥新用 [doctoral dissertation, Taipei Medical University]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0007-2712201715111900
- 蔡明宗（2009）。壹：開發新穎北極光激酶抑制劑於抗癌藥物之研究 貳：設計與合成新穎自溶酵素S抑制劑於抗癌症轉移之應用〔博士論文，國立清華大學〕。華藝線上圖書館。https://doi.org/10.6843/NTHU.2009.00326
- 張菱洳、孫仲銘（2000）。Applications of Solution-Phase Combinatorial Chemistry in Drug Discovery。化學，58(1)，103-116。https://doi.org/10.6623/chem.2000010